Pro-Pharma to get Federal Grants under QTDP program

The company said that the QTDP Program seeks to accelerate development of compounds that are novel and show great promise of success as treatments for disease.

Pro-Pharmaceuticals has submitted two grant applications; one for its Davanat anti-cancer compound, and a second grant for its GR-Series of anti-fibrotic, cirrhosis compounds, which have reversed liver fibrosis/cirrhosis in pre-clinical studies.

Pro-Pharmaceuticals executive chairman and co-founder James Czirr said that the funds will accelerate their pre-clinical trials with the goal of obtaining an Investigational New Drug application for human trials and a joint venture partner for our liver fibrosis compounds as soon as possible.

Pro-Pharmaceuticals CEO Theodore Zucconi said that they are pleased to receive these non-taxable grants from the federal government.

"We believe the grants for Davanat , our anti-cancer compound, and for GR-Series, our anti-fibrosis compounds, validate our drug development programs and approach for treating acute and chronic diseases with polysaccharides, Zucconi said.

"Our drug development programs were awarded the grants because our polysaccharides are novel, non-toxic, and because the Galectins they target are instrumental in the pathology of many diseases."